GLPG3667
TYK2
Small molecule
SLEDM
Focusing on high unmet medical needs, we synergize compelling science, technology, and collaborative approaches to create a deep pipeline of potential best-in-class therapies.
SLEDM
SLE: Systemic lupus erythematosus; DM: Dermatomyositis
1Collaboration with US WorldMeds
High-risk DLBCL with International Prognostic Index 3-5 or double/triple-hit lymphoma, primary refractory disease, defined as subjects failing to achieve a complete response to first-line anti-CD20 and anthracycline-based chemoimmunotherapy after ≥2 cycles at the interim disease assessment; IND: Investigational New Drug application; CTA: Clinical Trial Application; CAR T-cell therapy: Chimeric antigen receptor T cell therapy; TCR T-cell therapy: T cell receptor T cell therapy;
Clinical trials are a critical part of our journey to evaluate investigational treatments and gain approval from health authorities such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
At Galapagos, we organize clinical trials in various therapeutic areas, conducting research that paves the way for innovative solutions.
Visit our Clinical Trials portal to explore the fascinating world of clinical trials. Discover how they’re set up and gain insight into what’s important when considering participation.